Table I.
Demographics and characteristics of patients enrolled to TElmisartan plus AMlodipine STudy (TEAMSTA) Follow-Up studies.
| Variable | TEAMSTA-5 Follow-Up |
TEAMSTA-10 Follow-Up |
|---|---|---|
| Overall (N = 976) | Overall (N = 838) | |
| ← - - - - - - - - - - - - - - Mean (SD) - - - - - - - - - - - - - - → | ||
| SBP, mm Hg | 137.9 (13.9) | 138.2 (10.9) |
| DBP, mm Hg | 88.1 (8.7)† | 87.7 (6.8)⁎ |
| Age‡, y | 53.9 (10.6) | 56.4 (9.7) |
| BMI, kg/m2‡ | 29.2 (5.3) | 30.2 (4.6) |
| ← - - - - - - - - - - - - - - - - n (%) - - - - - - - - - - - - - - - - → | ||
| DBP at goal§ | 522 (54.1)† | 497 (59.5)⁎ |
| SBP/DBP at goal∥ | 381 (39.5)† | 372 (44.6)⁎ |
| Age ≥65‡, y | 162 (16.6) | 172 (20.5) |
| Males | 611 (62.6) | 471 (56.2) |
| Raceঠ| ||
| White | 746 (76.4) | 833 (99.4) |
| Asian | 211 (21.6) | 1 (0.1) |
| Black | 15 (1.5) | 1 (0.1) |
| Other | 4 (0.4) | 3 (0.3) |
| Duration of hypertension‡ | ||
| <1 y | 277 (28.4) | 105 (12.5) |
| <1–5 y | 340 (34.8) | 269 (32.1) |
| 6–10 y | 186 (19.1) | 230 (27.4) |
| >10 y | 173 (17.7) | 234 (27.9) |
| Diabetes‡ | 56 (5.7) | 77 (9.2) |
Add-on = additional antihypertensive medication; BMI = body mass index; DBP = diastolic blood pressure; SBP = systolic blood pressure; T40/A5 = telmisartan 40 mg plus amlodipine 5 mg; T40/A10 = telmisartan 40 mg plus amlodipine 10 mg; T80/A5 = telmisartan 80 mg plus amlodipine 5 mg; T80/A10 = telmisartan 80 mg plus amlodipine 10 mg.
⁎
n = 835.
†
n = 965.
‡
Recorded at baseline of respective TEAMSTA study.
§
<90 mm Hg.
∥
<140/90 mm Hg.
¶
Not recorded in 2 patients in TEAMSTA-10.